RFHE4043: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Rifaximin 550 mg in Subjects with Severe Hepatic Impairment and Overt Hepatic Encephalopathy

Project: Research project

Project Details

StatusFinished
Effective start/end date3/12/13 → 12/31/15

Funding

  • Valeant Pharmaceuticals North America LLC (RFHE4043 // RFHE4043)
  • Salix Pharmaceuticals, Inc. (RFHE4043 // RFHE4043)